Authors: Usman Najam, Joseph Iskander, Timothy Avino, Thomas Drago, Kristina Deonaraine, Arham Pasha
Published: 2024-10-09
DOI: 10.1161/res.135.suppl_1.we107
Source: Full article
Introduction: MitraClip has been shown to reduce heart failure readmissions in patients with moderate to severe mitral valve regurgitation. Likewise, beta-blocker (BB) therapy has been shown to reduce morbidity and mortality in select heart failure patients. At the cellular level, chronic myocardial insult from ongoing heart failure and mitral regurgitation leads to persistent overstimulation of myocardial beta-receptors, ultimately reducing cardiac inotropic reserve and contributing to myocardial injury. Thus, we hypothesized that patients on beta-blocker therapy before the MitraClip procedure would have fewer heart failure-related readmissions.